tetano
Editor, Senior Moderator
J Hematol Oncol
. 2022 Jan 10;15(1):4.
doi: 10.1186/s13045-021-01220-0.
Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leukemia
P Guisado-Vasco[SUP] 1 2 [/SUP], M M Carralón-González[SUP] 3 4 [/SUP], J Aguareles-Gorines[SUP] 5 [/SUP], E M Martí-Ballesteros[SUP] 6 [/SUP], M D Sánchez-Manzano[SUP] 3 4 [/SUP], D Carnevali-Ruiz[SUP] 3 4 5 6 7 8 9 10 [/SUP], M García-Coca[SUP] 7 [/SUP], R Barrena-Puertas[SUP] 3 4 [/SUP], R García de Viedma[SUP] 3 [/SUP], J M Luque-Pinilla[SUP] 3 4 [/SUP], G Sotres-Fernandez[SUP] 3 4 [/SUP], J M Fernández-Sousa[SUP] 8 [/SUP], X E Luepke-Estefan[SUP] 9 [/SUP], J A López-Martín[SUP] 10 [/SUP], J M Jimeno[SUP] 10 [/SUP]
Affiliations
Abstract
Background: There is an urgent need for highly efficacious antiviral therapies in immunosuppressed hosts who develop coronavirus disease (COVID-19), with special concern for those affected by hematological malignancies.
Case presentation: Here, we report the case of a 75-year-old male with chronic lymphocytic leukemia who was deficient in CD19[SUP]+[/SUP]CD20[SUP]+[/SUP] B-lymphocyte populations due to previous treatment with anti-CD20 monoclonal antibodies. The patient presented with severe COVID-19 pneumonia due to prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and was treated with two courses of the antiviral plitidepsin on a compassionate use basis. The patient subsequently achieved an undetectable viral load, and his pneumonia resolved.
Conclusions: Treatment with plitidepsin was well-tolerated without any further hematological or cardiovascular toxicities. This case further supports plitidepsin as a potential antiviral drug in SARS-CoV-2 patients affected by immune deficiencies and hematological malignancies.
Keywords: Anti-CD20 monoclonal antibody; Chronic lymphocytic leukemia; Covid-19; Plitidepsin; Prolonged viral replication; SARS-CoV-2.
. 2022 Jan 10;15(1):4.
doi: 10.1186/s13045-021-01220-0.
Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leukemia
P Guisado-Vasco[SUP] 1 2 [/SUP], M M Carralón-González[SUP] 3 4 [/SUP], J Aguareles-Gorines[SUP] 5 [/SUP], E M Martí-Ballesteros[SUP] 6 [/SUP], M D Sánchez-Manzano[SUP] 3 4 [/SUP], D Carnevali-Ruiz[SUP] 3 4 5 6 7 8 9 10 [/SUP], M García-Coca[SUP] 7 [/SUP], R Barrena-Puertas[SUP] 3 4 [/SUP], R García de Viedma[SUP] 3 [/SUP], J M Luque-Pinilla[SUP] 3 4 [/SUP], G Sotres-Fernandez[SUP] 3 4 [/SUP], J M Fernández-Sousa[SUP] 8 [/SUP], X E Luepke-Estefan[SUP] 9 [/SUP], J A López-Martín[SUP] 10 [/SUP], J M Jimeno[SUP] 10 [/SUP]
Affiliations
- PMID: 35012608
- DOI: 10.1186/s13045-021-01220-0
Abstract
Background: There is an urgent need for highly efficacious antiviral therapies in immunosuppressed hosts who develop coronavirus disease (COVID-19), with special concern for those affected by hematological malignancies.
Case presentation: Here, we report the case of a 75-year-old male with chronic lymphocytic leukemia who was deficient in CD19[SUP]+[/SUP]CD20[SUP]+[/SUP] B-lymphocyte populations due to previous treatment with anti-CD20 monoclonal antibodies. The patient presented with severe COVID-19 pneumonia due to prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and was treated with two courses of the antiviral plitidepsin on a compassionate use basis. The patient subsequently achieved an undetectable viral load, and his pneumonia resolved.
Conclusions: Treatment with plitidepsin was well-tolerated without any further hematological or cardiovascular toxicities. This case further supports plitidepsin as a potential antiviral drug in SARS-CoV-2 patients affected by immune deficiencies and hematological malignancies.
Keywords: Anti-CD20 monoclonal antibody; Chronic lymphocytic leukemia; Covid-19; Plitidepsin; Prolonged viral replication; SARS-CoV-2.